Disc Medicine Shares Jump 35% After Bitopertin Trial Revives Approval Hopes
Disc Medicine plans to resubmit its bitopertin application to the FDA after a late-stage trial met its goals. Shares rose 35%, Barron's reports.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Disc Medicine plans to reapply for FDA approval of its lead drug, bitopertin, after a late-stage trial met both its primary and secondary goals. The oral medication treats erythropoietic protoporphyria, a rare inherited disorder that makes patients extremely sensitive to light.
The company's shares, trading under the ticker IRON, surged 35% to $76.96 on Monday. If the gains hold, it will be Disc's biggest one-day percentage rise since December 2022, according to Dow Jones Market Data. The FDA rejected the earlier application in February, so the company now relies on Phase 3 data. A new application is planned by year-end, with a decision expected by mid-2027.
Cantor Fitzgerald analyst Kristen Kluska raised her probability-of-success estimate to 95% from 75%.
why it matters
For markets, the key point is that Disc may bring its first commercial product to market, which reduces uncertainty around its pipeline. Kluska notes that an active expanded access program could speed up sales after any approval. Source: Barron's.
market impact
Disc Medicine (IRON): stronger trial data raises odds of drug approval, supporting the stock
tags
instruments
sources
- Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes — Barrons.com, 19 October 2026 at 15:28 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗